Research
Future & OngoingRegistry
In 2013 we launched an ongoing cancer registry through an Institutional Review Board approved study at MD Anderson Cancer Center. The purpose of the research is to obtain information about diagnosis, stage, treatment and survival of women with this disease.
Clinical Trial
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
This phase II trial studies the effect of AK104 (cadonilimab) in treating high grade neuroendocrine carcinoma of the cervix. AK104 (cadonilimab) is a new type of immunotherapy drug. Immunotherapy with monoclonal antibodies, such as AK104 (cadonilimab), may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Prior studies with similar immunotherapy drugs in patients with high grade neuroendocrine carcinoma at multiple sites, including cervical, have shown disease regression in some of the patients. All patients enrolled on the trial will get AK104 (cadonilimab) and no patients will get placebo. This study has 18 spots for women with any type of high grade neuroendocrine cervical cancer.
E-mail our team for more information about the trial: nectur@mdanderson.org
Research Papers
Updates on Clinicopathologic Characteristics, Oncologic Outcomes, and Prognostic Factors in Neuroendocrine Cervical Carcinomas
MD Anderson Recommendations Guideline (2019)
This manuscript received the International Gynecologic Cancer Society (IGCS) 2020 award for Most Downloaded Paper.
Society of Gynecologic Oncology (SGO) Recommendation Guideline
Cervical Cancer Current FIGO Staging System
HPV and Neuroendocrine Cervical carcinomas
PET/CT scan improved detection of metastatic disease compared to CT scan alone
Early-Stage Neuroendocrine Carcinoma
Case Study 2021
The Role of Postoperative Radiation Therapy after radical hysterectomy in Early-Stage Neuroendocrine Carcinomas
Pelvic Radiation in Patients with Early-Stage and No Residual Disease
Radiation Therapy Improves Survival in Stage IVB Neuroendocrine Carcinomas
Case Study 2022
PARP and PDL-1 as potential therapeutic targets for Neuroendocrine Carcinomas
The Texas Cocktail: Combination Therapy with Topotecan, Paclitaxel, and Bevacizumab for Recurrent Neuroendocrine carcinomas
Single Agent Pembrolizumab for Recurrent Neuroendocrine Carcinomas
Comparative genomics of high grade neuroendocrine carcinoma of the cervix
RB1 Alteration and Poor Prognosis in Neuroendocrine Cervical Carcinomas
Social Media use is associated with higher levels of Anxiety and Depression in patients with Neuroendocrine Cervical Carcinomas
Interviews
IJGC Podcast
Dr. Michael Frumovitz is interviewed on the IJGC podcast in 2019.